ESMO Congress 2025 Confirms the Role of AI in Cancer Treatment

At the ESMO Congress 2025 held in Berlin, artificial intelligence demonstrated a pivotal role in reshaping cancer treatment through novel biomarker applications.
Studies presented at this event showed how AI models analyzing pathology images, imaging data, and genomic profiles can improve predictions of patient responses to therapies. For example, in metastatic colorectal cancer, AI identified patients who would likely benefit from the addition of immune checkpoint inhibitors by stratifying them into high- and low-biomarker groups. In mesothelioma, AI-assisted imaging combined with tumor heterogeneity genomic data effectively distinguished patients responsive to PARP inhibitors.
Similarly, non-small cell lung cancer studies illustrated that AI-derived imaging features outperformed traditional criteria in predicting treatment outcomes and early pathological responses.
These findings highlight a transformative shift toward precision oncology, where AI tools supplement clinical assessment by providing objective, reproducible, and early prediction of treatment benefits and risks. While integration into clinical practice is still evolving, this research underscores the potential for AI-driven biomarkers to guide personalized treatment decisions, optimize therapeutic efficacy, and limit unnecessary toxicity across diverse cancer types.

Source.